In vitro digestion kinetics of excipients for lipid-based drug delivery and introduction of a relative lipolysis half life

Drug Development and Industrial Pharmacy

Volumn 38, Issue 10, 2012, Pages 1262-1269

  Arnold, Yvonne E ^a,b   Imanidis, Georgios ^a,b   Kuentz, Martin ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

Author keywords

Biorelevant test; Kinetic model; Lipid formulations; Lipolysis; Lipolysis degree; Pharmaceutical additives

Indexed keywords

CAPRYOL; CREMOPHOR; DIACYLGLYCEROL; DRUG ADDITIVE; EXCIPIENT; GELUCIRE; IMWITOR; LAUROGLYCOL; LIPID; MEDIUM CHAIN TRIACYLGLYCEROL; MIGLYOL; MONOACYLGLYCEROL; OCTANOIN; PEGLICOL 5 OLEATE; POLYSORBATE 80; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; DIGESTION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HALF LIFE TIME; IN VITRO STUDY; KINETICS; LIPOLYSIS; MATHEMATICAL MODEL; PH;

ADMINISTRATION, ORAL; DIGESTION; DRUG DELIVERY SYSTEMS; EXCIPIENTS; GASTROINTESTINAL TRACT; HALF-LIFE; HYDROGEN-ION CONCENTRATION; KINETICS; LIPIDS; LIPOLYSIS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; SODIUM HYDROXIDE; SOLUBILITY; TRIGLYCERIDES;

EID: 84866241046     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.645834     Document Type: Article

References (31)

1. Loftsson T, Brewster ME. (2010). Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol, 62:1607-1621.
2. Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785-796. (Pubitemid 39242830)
3. Veiga MD, Díaz PJ, Ahsan F. (1998). Interactions of griseofulvin with cyclodextrins in solid binary systems. J Pharm Sci, 87: 891-900. (Pubitemid 28319422)
4. Pouton CW. (2000). Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci, 11 Suppl 2:S93-S98.
5. Christiansen A, Backensfeld T, Weitschies W. (2010). Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes. Eur J Pharm Sci, 41:376-382.
6. O'Driscoll CM. (2002). Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci, 15:405-415. (Pubitemid 34567104)
7. Kuentz M. (2011). Oral self-emulsifying drug delivery systems, from biopharmaceutical to technical formulation aspects. J Drug Deliv Sci Technol, 21:17-26.
8. Christensen JOø, Schultz K, Mollgaard B, Kristensen HG, Mullertz A. (2004). Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. Eur J Pharm Sci, 23:287-296. (Pubitemid 39369884)
9. Dahan A, Hoffman A. (2007). The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm, 67:96-105. (Pubitemid 46991342)
10. Kaukonen AM, Boyd BJ, Porter CJ, Charman WN. (2004). Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations. Pharm Res, 21:245-253. (Pubitemid 38221969)
11. Porter CJ, Kaukonen AM, Taillardat-Bertschinger A, Boyd BJ, O'Connor JM, Edwards GA et al. (2004). Use of in vitro lipid digestion data to explain the in vivo performance of triglyceridebased oral lipid formulations of poorly water-soluble drugs: studies with halofantrine. J Pharm Sci, 93:1110-1121. (Pubitemid 38529685)
12. MacGregor KJ, Embleton JK, Lacy JE, Perry AE, Solomon J, Seager H, Pouton CW. (1997). Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv Drug Del Rev, 25:33-46. (Pubitemid 27107789)
13. Fernandez S, Chevrier S, Ritter N, Mahler B, Demarne F, Carrière F et al. (2009). In vitro gastrointestinal lipolysis of four formulations of piroxicam and cinnarizine with the self emulsifying excipients Labrasol and Gelucire 44/14. Pharm Res, 26:1901-1910.
14. Reymond JP, Sucker H. (1988). In vitro model for ciclosporin intestinal absorption in lipid vehicles. Pharm Res, 5:673-676. (Pubitemid 18263617)
15. Sek L, Porter CJ, Kaukonen AM, Charman WN. (2002). Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. J Pharm Pharmacol, 54:29-41. (Pubitemid 34116220)
16. Zangenberg NH, Müllertz A, Kristensen HG, Hovgaard L. (2001). A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. Eur J Pharm Sci, 14:115-122. (Pubitemid 32737533)
17. Goddeeris C, Coacci J, Van den Mooter G. (2007). Correlation between digestion of the lipid phase of smedds and release of the anti-HIV drug UC 781 and the anti-mycotic drug enilconazole from smedds. Eur J Pharm Biopharm, 66:173-181. (Pubitemid 46654766)
18. Aloulou A, Rodriguez JA, Fernandez S, van Oosterhout D, Puccinelli D, Carrière F. (2006). Exploring the specific features of interfacial enzymology based on lipase studies. Biochim Biophys Acta, 1761:995-1013. (Pubitemid 44354291)
19. Panaiotov I, Ivanova M, Verger R. (1997). Interfacial and temporal organization of lipolysis. Curr Opin Colloid In, 2:517-525.
20. Verger R, de Haas GH. (1976). Interfacial enzyme kinetics of lipolysis. Annu Rev Biophys Bioeng, 5:77-117.
21. Laidler KJ, Bunting PS. (1973). The chemical kinetics of enzyme action. Clarendon, Oxford.
22. Kosugi Y, Suzuki H. (1983). New parameters for simulating progress curves of the lipase reaction. J Ferment Technol, 61:287-294.
23. Knezevic ZD, Siler-Marinkovic SS, Mojovic LV. (1998). Kinetics of lipase-catalyzed hydrolysis of palm oil in lecithin/isooctane reversed micelles. Appl Microbiol Biotechnol, 49:267-271. (Pubitemid 28172639)
24. Embleton JK, Pouton CW. (1997). Structure and function of gastrointestinal lipases. Adv Drug Del Rev, 25:15-32.
25. Jantratid E, Janssen N, Reppas C, Dressman JB. (2008). Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res, 25:1663-1676.
26. Arnold Y, Gonzalez RB, Versace H, Kuentz M. (2010). Comparison of different in vitro tests to assess oral lipid-based formulations using a poorly soluble acidic drug. J Drug Del Sci Tech, 20:143-148.
27. Gargouri Y, Julien R, Bois AG, Verger R, Sarda L. (1983). Studies on the detergent inhibition of pancreatic lipase activity. J Lipid Res, 24:1336-1342.
28. Cuiné JF, McEvoy CL, Charman WN, Pouton CW, Edwards GA, Benameur H, Porter CJH. (2007). Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J Pharm Sci, 97, 993-1010.
29. Fatouros DG, Mullertz A. (2008). In vitro lipid digestion models in design of drug delivery systems for enhancing oral bioavailability. Expert Opin Drug Metab Toxicol, 4:65-76. (Pubitemid 351234101)
30. Warren DB, Anby MU, Hawley A, Boyd BJ. (2011). Real time evolution of liquid crystalline nanostructure during the digestion of formulation lipids using synchrotron small-angle X-ray scattering. Langmuir, 27:9528-9534.
31. Ali H, Nazzal M, Zaghloul AA, Nazzal S. (2008). Comparison between lipolysis and compendial dissolution as alternative techniques for the in vitro characterization of α-tocopherol self-emulsified drug delivery systems (SEDDS). Int J Pharm, 352:104-114.